Press Enter to search · ESC to close

Crypto

NMPA Approves Beijing Immunochina’s CAR-T Therapy for Large B-Cell Lymphoma

China’s National Medical Products Administration has approved 泊基奥仑赛注射液 (brand name: 赛泊华), a CAR-T therapy developed by Beijing Immunochina Biopharmaceutical Co., Ltd., for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The indication covers diffuse large B-cell lymphoma not otherwise specified, grade 3b follicular lymphoma and high-grade B-cell lymphoma.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback